Skip to main content
. Author manuscript; available in PMC: 2022 Jul 16.
Published in final edited form as: Immunity. 2022 Mar 8;55(3):512–526.e9. doi: 10.1016/j.immuni.2022.02.005

Figure 1. CD226 deficiency reduces efficacy of PD-1 and TIGIT checkpoint blockade and impairs CD8+ T cell responses.

Figure 1.

(A) BALB/c WT or Cd226−/− mice inoculated with syngeneic CT26 tumor cells and treated with isotype control, anti-PD-1, or anti-TIGIT antibodies. Tumor growth was monitored and grouped analysis and growth curves for each individual animal (n = 10 per group) are shown. Tumor volume remaining below 32 mm3 was considered to be a complete response (CR). p values are shown for end of study at day 23 using two-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.001; ns, not significant.

(B) CD226 deficiency impairs cytotoxicity of CD8+ T cells. WT OT-I cells (black lines) or Cd226−/− OT-I cells (red lines) were used as effector cells against B16F10 melanoma or PVR/PVRL2-deficient (PVR−/−PVRL2−/−) B16F10 target cells pulsed with OVA (SIINFEKL) peptide. Representative real-time profiling of killing is shown on the left panel. Scatterplot (right panel) shows percent cytotoxicity at the 3 h time point. Data are shown as mean ± SD of three independent experiments. p values are shown for one-way ANOVA test with post hoc Tukey’s multiple comparisons; *p < 0.05; **p < 0.01; ***p < 0.0001.